论文部分内容阅读
目的:探讨川芎嗪注射液联合无创正压通气治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果。方法:选取2012年10月—2015年10月我院收治的300例慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者的临床资料进行研究分析,按选取治疗手段的不同分为对照组和研究组,其中对照组100例,研究组200例。对照组患者接受激素、抗生素、支气管扩张剂、呼吸兴奋剂进行常规酸碱纠正治疗,同时给予无创通气治疗,研究组患者在此基础上给予川芎嗪注射液治疗。主要检测指标为:用力肺活量(FCV)、1 s用力呼吸容积(FEV1)、FEV1占预计值得百分比(FEV1%);两组患者心率、呼吸频率、血气分析结果、气管插管率、并发症出现率以及病死率。结果:治疗后两组患者肺功能均有所改善,但是研究组FEV1、FEV1/FCV、FEV1%指标改善情况均明显优于对照组,P<0.05,差异具有统计学意义;两组患者呼吸频率、心率、二氧化碳分压(Pa CO2)均下降,氧分压(Pa O2)均升高,但研究组患者改善情况优于对照组,P<0.05,差异具有统计学意义;两组患者在气管插管率、死亡率、总有效率上的差异具有统计意义,P<0.05。结论:在常规治疗基础上给予川芎嗪注射液治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭临床症状改善明显、疗效良好、值得临床推广应用。
Objective: To investigate the effect of ligustrazine injection combined with noninvasive positive pressure ventilation in the treatment of chronic obstructive pulmonary disease (COPD) complicated with type Ⅱ respiratory failure. Methods: From October 2012 to October 2015 in our hospital admitted to 300 cases of chronic obstructive pulmonary disease with type Ⅱ respiratory failure in patients with clinical data analysis, according to the selection of treatment is divided into control group and study group, 100 cases in the control group and 200 cases in the study group. Patients in the control group received steroid, antibiotics, bronchodilators, and respiratory stimulants for routine acid-base correction, while noninvasive ventilation was given. Patients in the study group were given ligustrazine injection on this basis. The main test indicators were forced vital capacity (FCV), forced expiratory volume at 1 second (FEV1) and FEV1 (FEV1%). The heart rate, respiratory rate, blood gas analysis results, tracheal intubation rate and complications Rate and fatality rate. Results: The lung function of both groups improved after treatment, but the improvement of FEV1, FEV1 / FCV and FEV1% of the study group were significantly better than the control group, P <0.05, the difference was statistically significant. The respiratory rate (P <0.05), the heart rate, PaCO 2 decreased and PaO 2 increased, but the improvement of the study group was better than that of the control group, P <0.05, the difference was statistically significant; the two groups of patients in the trachea Intubation rate, mortality, total effective rate difference was statistically significant, P <0.05. CONCLUSION: The clinical symptoms of chronic obstructive pulmonary disease combined with respiratory failure of type Ⅱ are obviously improved and the curative effect is good after the administration of ligustrazine on the basis of routine treatment, which is worthy of clinical application.